Review IDs modifiers of cancer risk in BRCA1/2 carriers

May 23, 2014
Review IDs modifiers of cancer risk in <i>BRCA1/2</i> carriers

(HealthDay)—Modifiers of cancer risk have been identified for BRCA1/2 mutation carriers, according to a review published online May 13 in the Journal of the National Cancer Institute.

Tara M. Friebel, M.P.H., from the University of Pennsylvania Perelman School of Medicine in Philadelphia, and colleagues conducted a systematic review of the literature to identify factors that are associated with cancer risk modification in BRCA1/2 mutation carriers. Forty-four non-overlapping studies that met predefined quality criteria were included in fixed effects meta-analyses.

The researchers found that the only variable that produced a probable association was late age at first live birth, which was associated with a decreased risk of in BRCA1 mutation carriers (effect estimate: 0.65; 95 percent confidence interval, 0.42 to 0.99 for women aged 30 years or older versus women aged younger than 30 years). A similar association was seen for women aged 25 to 29 years versus those aged younger than 25 years (effect estimate, 0.69; 95 percent confidence interval, 0.48 to 0.99). For BRCA1 mutation carriers, breastfeeding and tubal ligation correlated with reduced ovarian cancer risk, while for BRCA1/2 carriers, oral contraceptives correlated with reduced risk. In BRCA2 mutation carriers only, smoking correlated with increased .

"There is a critical need for improved risk assessment for women with BRCA1/2 mutations and a need to reduce risk in this high-risk population," the authors write. "The data presented here may be of value in developing more meaningful risk assessment tools, including statistical models, and approaches for reducing in BRCA1/2 mutation carriers."

Explore further: Pill effects on breast, ovarian CA same in high-risk women

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Pill effects on breast, ovarian CA same in high-risk women

October 22, 2013
(HealthDay)—Among women who are BRCA1/2 mutation carriers, the associations between ever use of oral contraceptives (OCs) and ovarian and breast cancers are similar to those observed in the general population, according ...

Study shows breastfeeding, birth control may reduce ovarian cancer risk in women with BRCA mutations

May 14, 2014
Breastfeeding, tubal ligation – also known as having one's "tubes tied" – and oral contraceptives may lower the risk of ovarian cancer for some women with BRCA gene mutations, according to a comprehensive analysis from ...

Diagnostic chest radiation before 30 may increase breast cancer risk

September 6, 2012
Women carrying a mutation in the BRCA1- or BRCA2- genes (which control the suppression of breast and ovarian cancer) who have undergone diagnostic radiation to the chest before the age of 30 are more likely to develop breast ...

BRCAPRO model underestimates BRCA1/2 mutation risk

March 21, 2014
(HealthDay)—Use of the BRCAPRO model for assessment of the likelihood of having a germline BRCA1/BRCA2 mutation, based on age, ethnicity, and family history, may underestimate the risk of mutations, according to a study ...

Polygenic risk score helpful for women with familial breast CA

December 18, 2012
(HealthDay)—For women affected by familial breast cancer, a polygenic risk score based on 22 genomic variants can identify women at high-risk of breast cancer, according to a study published in the Dec. 10 issue of the ...

Recommended for you

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

Discovery could lead to better results for patients undergoing radiation

July 19, 2017
More than half of cancer patients undergo radiotherapy, in which high doses of radiation are aimed at diseased tissue to kill cancer cells. But due to a phenomenon known as radiation-induced bystander effect (RIBE), in which ...

Definitive genomic study reveals alterations driving most medulloblastoma brain tumors

July 19, 2017
The most comprehensive analysis yet of medulloblastoma has identified genomic changes responsible for more than 75 percent of the brain tumors, including two new suspected cancer genes that were found exclusively in the least ...

Novel CRISPR-Cas9 screening enables discovery of new targets to aid cancer immunotherapy

July 19, 2017
A novel screening method developed by a team at Dana-Farber/Boston Children's Cancer and Blood Disorders Center—using CRISPR-Cas9 genome editing technology to test the function of thousands of tumor genes in mice—has ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.